Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS unified agenda

This article was originally published in The Tan Sheet

Executive Summary

FDA will begin reviewing nutrient content "high potency" and "antioxidant" claims this month and plans to complete the work in September 2007, according to the Health & Human Services Department's semi-annual "unified agenda" published in the Dec. 11 Federal Register. FDA also plans to publish a final rule on claims antihistamines can make for the common cold in June 2007, according to the unified agenda. The agency will announce a notice of proposed rulemaking in October 2007 to add Stevens-Johnson warnings on OTC analgesics. It intended to issue the proposed rule in June 2006, according to the previous unified agenda (1"The Tan Sheet" May 15, 2006, p. 8). FDA plans to issue an NPRM in May to "address oral healthcare products used to reduce or prevent dental plaque or gingivitis," the agenda says...

You may also be interested in...

FDA Agenda Slates Stevens-Johnson Proposal For June; GMPs In December?

FDA intends to issue a proposed rule to add a warning about Stevens-Johnson Syndrome to the NSAID allergy label in June, the agency announces in HHS' semi-annual "unified agenda.

TTS Pharma Wants To Bring First Legal CBD Oil To The UK

TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts